Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
NCT00732147 · University of Maryland, Baltimore · NA · withdrawn · last registry update 2021-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor could not fund.” | – | Registry record, University of Maryland, Baltimore |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-26Results posted on the registry: Joslin Diabetes Center, Pramlintide (NCT01841359)
- 2022-03-28Also stopped (terminated): University of Virginia, a drug against CALCR (NCT03547427)
- 2021-08-09Results posted on the registry: Novartis Pharmaceuticals, Erenumab + Topiramate (NCT03828539)
- 2021-07-14Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Lenvatinib + Sorafenib (NCT03630120)
- 2021-06-10Results posted on the registry: University of Maryland, Baltimore, Calcitonin (NCT03342001)
- 2021-03-09Results posted on the registry: Novartis Pharmaceuticals, Erenumab (NCT03333109)
- 2021-01-22Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Lenvatinib + Sorafenib (NCT03630120)
- 2020-10-20Results posted on the registry: Texas Diabetes & Endocrinology, P.A., a drug against CALCR (NCT00790699)
- 2020-10-20Also stopped (terminated): Texas Diabetes & Endocrinology, P.A., a drug against CALCR (NCT00790699)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision